ArticleRespiratory research2025
The role of eCyPA as an inflammatory biomarker for predicting 28-day mortality in ARDS patients.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The landscape of protein post-translational modifications in the pathogenesis of acute respiratory distress syndrome.Journal of thoracic disease · 2026Review
- Regular exposure to low dose of diarrheic shellfish toxins: Implications for the seafood consumer.Current research in food science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAcute respiratory distress syndrome (ARDS) is the primary manifestation of systemic inflammatory response syndrome in the lungs. Extracellular cyclophilin A (eCyPA) as a novel inflammatory marker, this study aims to investigate the expression of eCyPA in ARDS and its relationship with patient prognosis.
methodsThis retrospective study collected serum samples from adult patients diagnosed with acute respiratory distress syndrome (ARDS) upon their admission to ICU. Additionally, venous blood and bronchoalveolar lavage fluid were obtained from a lipopolysaccharide (LPS)-induced ARDS mouse model. The expression levels of extracellular cyclophilin A in serum and bronchoalveolar lavage fluid were quantified using enzyme-linked immunosorbent assay (ELISA). The data collection period extended from December 2021 to December 2023. Binary logistic regression analysis, ROC curve, Kaplan-Meier survival analysis were employed to evaluate the correlation with 28-day all-cause mortality in ARDS patients. An incremental prognostic value analysis was conducted to further investigate the enhancement in predictive value when combined with clinically significant indicators (platelet count and oxygenation index). Additionally, we assessed the dynamic trends of eCyPA and cytokines in serum and bronchoalveolar lavage fluid at 0, 1, 3, and 7 days in LPS-induced ARDS mouse models.
resultsA total of 50 patients were enrolled. The serum eCyPA expression level was significantly higher among non-survivors compared to survivors (7.2 ng/ml, interquartile range, IQR, 5.9-8.2 vs. 10.1 ng/ml, IQR 7.5-10.6; p = 0.002), and this finding remained consistent across various subgroups. eCyPA is an effective predictor of 28-day mortality in ARDS patients (AUC = 0.754). When combined with platelet count and oxygenation index, the prognostic value assessment improved the AUC to 0.887 (P < 0.001). In ARDS mice, eCyPA increased continuously over 7 days in serum and bronchoalveolar lavage fluid, the trend is similar to inflammatory cytokines in ARDS mice.
conclusionsThe findings suggest that eCyPA may serve as a potential biomarker for predicting 28-day mortality in patients with acute respiratory distress syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.